Selection of patients for nerve sparing surgery in robot-assisted radical prostatectomy.

erectile dysfunction evidence synthesis nerve‐sparing prostate cancer radical prostatectomy systematic review

Journal

BJUI compass
ISSN: 2688-4526
Titre abrégé: BJUI Compass
Pays: United States
ID NLM: 101764975

Informations de publication

Date de publication:
Jan 2022
Historique:
received: 30 07 2021
revised: 13 09 2021
accepted: 18 09 2021
entrez: 27 4 2022
pubmed: 28 4 2022
medline: 28 4 2022
Statut: epublish

Résumé

Robot-assisted radical prostatectomy (RARP) has become the standard surgical procedure for localized prostate-cancer (PCa). Nerve-sparing surgery (NSS) during RARP has been associated with improved erectile function and continence rates after surgery. However, it remains unclear what are the most appropriate indications for NSS. The objective of this study is to systematically review the available parameters for selection of patients for NSS. The weight of different clinical variables, multiparametric magnetic-resonance-imaging (mpMRI) findings, and the impact of multiparametric-nomograms in the decision-making process on (side-specific) NSS were assessed. This systematic review searched relevant databases and included studies performed from January 2000 until December 2020 and recruited a total of 15 840 PCa patients. Studies were assessed that defined criteria for (side-specific) NSS and associated them with oncological safety and/or functional outcomes. Risk of bias assessment was performed. Nineteen articles were eligible for full-text review. NSS is primarily recommended in men with adequate erectile function, and with low-risk of extracapsular extension (ECE) on the side-of NSS. Separate clinical and radiological variables have low accuracy for predicting ECE, whereas nomograms optimize the risk-stratification and decision-making process to perform or to refrain from NSS when oncological safety (organ-confined disease, PSM rates) and functional outcomes (erectile function and continence rates) were assessed. Consensus exists that patients who are at high risk of ECE should refrain from NSS. Several multiparametric preoperative nomograms were developed to predict ECE with increased accuracy compared with single clinical, pathological, or radiological variables, but controversy exists on risk thresholds and decision rules on a conservative versus a less-conservative surgical approach. An individual clinical judgment on the possibilities of NSS set against the risks of ECE is warranted. NSS is aimed at sparing the nerves responsible for erection. NSS may lead to unfavorable tumor control if the risk of capsule penetration is high. Nomograms predicting extraprostatic tumor-growth are probably most helpful.

Identifiants

pubmed: 35475150
doi: 10.1002/bco2.115
pii: BCO2115
pmc: PMC8988739
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

6-18

Informations de copyright

© 2021 The Authors. BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company.

Références

JAMA. 1997 May 14;277(18):1445-51
pubmed: 9145716
J Urol. 2005 Oct;174(4 Pt 1):1262-5
pubmed: 16145389
Lancet Oncol. 2011 Sep;12(9):891-9
pubmed: 21821474
J Urol. 2003 Jun;169(6):2147-52
pubmed: 12771737
J Urol. 2014 Jul;192(1):82-8
pubmed: 24440235
N Engl J Med. 2016 Oct 13;375(15):1425-1437
pubmed: 27626365
Eur Urol. 2019 Oct;76(4):505-514
pubmed: 30979636
Eur Urol. 2013 Mar;63(3):438-44
pubmed: 22901982
J Urol. 1999 Feb;161(2):494-8; discussion 498-9
pubmed: 9915434
Urol Oncol. 2020 May;38(5):372-378
pubmed: 32088104
Eur Urol. 2014 Jul;66(1):138-44
pubmed: 24411279
Urology. 1998 Mar;51(3):437-42
pubmed: 9510349
J Urol. 2006 Mar;175(3 Pt 1):939-44; discussion 944
pubmed: 16469587
Korean J Urol. 2013 Jul;54(7):437-41
pubmed: 23878685
Radiology. 2012 Mar;262(3):874-83
pubmed: 22274837
Br J Radiol. 2018 Apr;91(1084):20170736
pubmed: 29243485
Urol Clin North Am. 1990 Nov;17(4):819-26
pubmed: 2219579
Eur Urol. 2021 Feb;79(2):180-185
pubmed: 33023770
Eur Urol. 2014 Feb;65(2):303-13
pubmed: 23932439
Urology. 2019 Jul;129:8-20
pubmed: 30928608
BJUI Compass. 2021 Nov 09;3(1):6-18
pubmed: 35475150
Eur Urol. 2010 Aug;58(2):281-7
pubmed: 20417025
Eur Radiol. 2019 Oct;29(10):5478-5487
pubmed: 30887199
Eur J Radiol. 2013 Oct;82(10):1677-82
pubmed: 23773553
Eur Urol Focus. 2018 Apr;4(3):351-359
pubmed: 28753802
Urology. 2016 Feb;88:119-24
pubmed: 26545849
J Endourol. 2018 Apr;32(4):315-321
pubmed: 29256639
Eur Urol. 2016 Aug;70(2):233-45
pubmed: 26215604
Urol Oncol. 2013 Nov;31(8):1497-503
pubmed: 22591746
BJU Int. 2019 Aug;124(2):192-194
pubmed: 30657243
J Urol. 2003 Nov;170(5):1798-803
pubmed: 14532779
J Urol. 2004 May;171(5):1844-9; discussion 1849
pubmed: 15076291
BJU Int. 2018 Mar;121(3):373-382
pubmed: 28941058
Eur Urol. 2012 Sep;62(3):418-30
pubmed: 22749850
J Urol. 2017 Oct;198(4):760-769
pubmed: 28286069
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1626-1638
pubmed: 33604691
J Endourol. 2008 Jun;22(6):1303-9
pubmed: 18484875
J Urol. 2018 May;199(5):1202-1209
pubmed: 29253578
BJU Int. 2018 Dec;122(6):1025-1033
pubmed: 29676063
Br J Cancer. 2012 Feb 14;106(4):638-45
pubmed: 22274410
Urology. 1998 Nov;52(5):814-8; discussion 818-9
pubmed: 9801105
J Robot Surg. 2017 Jun;11(2):129-138
pubmed: 27435701
Eur Urol. 2012 Sep;62(3):405-17
pubmed: 22749852
Urology. 2010 Sep;76(3):743-8
pubmed: 20573384
Can J Urol. 2019 Feb;26(1):9644-9653
pubmed: 30797247
J Urol. 2001 Mar;165(3):857-63
pubmed: 11176486
Eur Urol Focus. 2020 Nov 15;6(6):1205-1212
pubmed: 30477971
Scand J Urol. 2019 Dec;53(6):385-391
pubmed: 31797716
Urol Clin North Am. 1987 Nov;14(4):663-73
pubmed: 3314061
BJU Int. 2017 Aug;120(2):185-196
pubmed: 28319318
Urol Oncol. 2019 Mar;37(3):181.e1-181.e6
pubmed: 30558983
Eur Urol. 2017 Apr;71(4):618-629
pubmed: 27568654
Eur Urol. 2019 Dec;76(6):814-822
pubmed: 30514568
Eur Urol. 2018 Feb;73(2):290-300
pubmed: 28917594
Eur Urol. 2007 Jan;51(1):90-7
pubmed: 17074431
Prostate Cancer Prostatic Dis. 2019 Sep;22(3):391-398
pubmed: 30504811
Urol Oncol. 2010 Mar-Apr;28(2):215-8
pubmed: 20219562
Eur Urol. 2016 Apr;69(4):584-589
pubmed: 26277303
J Urol. 2020 Jul;204(1):91-95
pubmed: 31971494
Transl Androl Urol. 2020 Apr;9(2):437-444
pubmed: 32420149
J Endourol. 2015 Dec;29(12):1396-405
pubmed: 26154571
Cancer. 2004 Jun 15;100(12):2655-63
pubmed: 15197809
Br J Urol. 1984 Dec;56(6):694-7
pubmed: 6534493
Urology. 2009 Sep;74(3):619-23
pubmed: 19592075
Eur Urol. 2015 Oct;68(4):692-704
pubmed: 25454614
Jpn J Clin Oncol. 2010 Apr;40(4):343-8
pubmed: 19959505
Eur Urol. 2015 Mar;67(3):559-68
pubmed: 25457018
BJU Int. 2017 May;119(5):676-683
pubmed: 27367645

Auteurs

André N Vis (AN)

Department of Urology Amsterdam UMC, Location VUmc Amsterdam The Netherlands.
Prostate Cancer Network Netherlands.

Roderick C N van den Bergh (RCN)

Department of Urology Antonius Hospital Nieuwegein The Netherlands.

Henk G van der Poel (HG)

Prostate Cancer Network Netherlands.
Department of Urology NKI/AVL Amsterdam The Netherlands.

Alexander Mottrie (A)

Department of Urology Onze Lieve Vrouw Hospital (OLV) Aalst Belgium.

Philip D Stricker (PD)

Department of Urology St. Vincent's Clinic Sydney NSW Australia.

Marcus Graefen (M)

Martini-Klinik University Hospital Hamburg-Eppendorf Hamburg Germany.

Vipul Patel (V)

Global Robotics Institute Florida Hospital Celebration Health Orlando Florida USA.

Bernardo Rocco (B)

Department of Urology University of Modena and Reggio Emilia Modena Italy.

Birgit Lissenberg-Witte (B)

Department of Epidemiology and Data Science Amsterdam UMC, Location VUmc Amsterdam The Netherlands.

Pim J van Leeuwen (PJ)

Prostate Cancer Network Netherlands.
Department of Urology NKI/AVL Amsterdam The Netherlands.

Classifications MeSH